Virax Biolabs Group Limited (NASDAQ: VRAX) Stock Information | RedChip

Virax Biolabs Group Limited (NASDAQ: VRAX) Listen to this Section


$1.43
-0.3000 ( -17.30% ) 1.4M

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Market Data


Open


$1.43

Previous close


$1.73

Volume


1.4M

Market cap


$3.28M

Day range


$1.40 - $1.72

52 week range


$0.60 - $4.00

Insider Ownership Transactions

Total Amount Purchased: 0.00 | $ 0.00

Date Type Amount Purchased Purchaser
No records found.

SEC Fillings


Form Type Description Pages Date
nt Quarterly Reports 1 Aug 01, 2024
6-k Quarterly Reports 1 Jun 11, 2024
6-k Quarterly Reports 2 Apr 25, 2024
6-k Quarterly Reports 2 Apr 16, 2024
6-k Quarterly Reports 2 Mar 15, 2024
6-k Quarterly Reports 3 Jan 22, 2024
6-k Quarterly Reports 3 Jan 12, 2024
6-k Quarterly Reports 2 Dec 21, 2023
6-k Quarterly Reports 3 Dec 20, 2023
6-k Quarterly Reports 2 Dec 18, 2023

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.